Protocol Library - Altai Oncology Software

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols forms the basis of all our Oncology software solutions

Over 1,000 cancer treatment protocols

Medical Oncology, Hematology, Bone Marrow Transplantation

With administration details, lab parameters, indications, and summarized references

Updated monthly to include latest approvals and major papers

Reviewed by Medical Oncologists and Hematologists

GastroEsophageal Cancer

New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Ulas D. Bayraktar, MD

Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Ulas D. Bayraktar, MD

Mesothelioma

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

Ulas D. Bayraktar, MD

Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

Ulas D. Bayraktar, MD

Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Ulas D. Bayraktar, MD

Breast Cancer

New Protocol: Eribulin for Breast Cancer

Ulas D. Bayraktar, MD

Small Cell Lung Cancer

New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

Ulas D. Bayraktar, MD

GastroEsophageal Cancer

New Drug: Zolbetuximab with FOLFOX for Gastric and GE Junction Cancer

Phase 3, multicenter, randomized, double-blind trial (SPOTLIGHT) Locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, CLDN18.2-positive,

Non-Small Cell Lung Cancer

New Indication: Osimertinib after Chemoradiotherapy in NSCLC

Phase 3, double-blind, placebo-controlled trial (LAURA) Locally advanced, unresectable stage III NSCLC with EGFR exon 19 deletion or L858R mutation after chemoradiation Osimertinib

Non-Small Cell Lung Cancer

New Drug: Lazertinib for EGFR mutated NSCLC

Type: Phase 3, international, randomized trial Population: Patients with previously untreated EGFR-mutated advanced NSCLC (Ex19del or L858R) Treatment: Amivantamab–lazertinib vs.

Small Cell Lung Cancer

New Drug: Tarlatamab for SCLC

Phase 2, open-label (DeLLphi-301) Relapsed/refractory to platinum-based therapy Advanced SCLC Tarlatamamab 10 or 100 mg => Final dose selected as 10 mg

New Reference: Pembrolizumab with CISplatin and PEMEtrexed in Mesothelioma

J Clin Oncol 2023 41:17_suppl, LBA8505 Chu QS IND227 phase III (P3) study of cisplatin/pemetrexed (CP) with or without pembrolizumab (pembro) in patients (pts) with malignant pleur

Multiple Myeloma

New Reference: Daratumumab with Lenalidomide and Bortezomib in 1st Line Multiple Myeloma

Lancet Haematol 2023 Oct;10(10):e825-e837 Voorhees PM Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagno

Non-Small Cell Lung Cancer

New Drug: Amivantamab for NSCLC

Phase 3, international, randomized trial (PAPILLON) Advanced NSCLC with EGFR exon 20 insertions who had not received previous systemic therapy Amivantamab + Chemoterapy (n=153) vs.

New Protocol: Eribulin for Breast Cancer

J Clin Oncol 2015;33(6):594-601 Kaufman PA Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast can

Small Cell Lung Cancer

New Indication: Repotrectinib for NTRK-Fusion Positive Solid Tumors

Advanced NTRK-fusion+ solid tumors (TRIDENT-1) TKI-naive (n=40) and TKI-pretreated (n=48)

Our Solutions

Altai Protocol Library

Our protocol library curated since 2015 with over 1,000 protocols

Altai Oncology Suite

Our premiere, CE-marked, Windows application designed for cancer centers

Altai Oncology App

Easiest access to our protocol library on your hands

Altai Chemo Planner

Core features of Altai Oncology Suite for the solo Oncologist/Hematologist

Articles

Computerized Chemotherapy Order Entry

The Power of a Protocol Library: Standardizing Oncology Care Across Institutions

Oncology care is inherently complex — with evolving treatment regimens, biomarker-specific indications, organ-based dosing, and rapidly changing guidelines. In this landscape, consistency and clarity become essential not only for safety, but also for quality and equity. This is where a centralized protocol library becomes a game-changer …

From Protocol to Pharmacy: Ensuring Seamless Chemotherapy Order Handover

Chemotherapy isn’t just about selecting a protocol — it’s about delivering it safely, on time, and without miscommunication. This article walks through the full treatment workflow from oncologist to pharmacist to infusion nurse, and shows how Altai Oncology creates a unified, structured order that eliminates delays, errors, and manual rework.

Back to top Drag